Bad news for breast cancer patients in the UK as the National Institute for Health and Care Excellence announces it has decided to reject AstraZeneca’s Faslodex (fulvestrant) on the basis that it cannot reconcile its cost-effectiveness for use on the NHS.
AZ had been hoping to secure the drug’s routine use on the health service in the treatment of locally advanced or metastatic oestrogen-receptor positive breast cancer in postmenopausal women who have not undergone prior endocrine therapy.
